相关实验视频

Updated: Jul 21, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

新辅助免疫化学疗法与仅用于局部晚期食道状细胞癌的化疗:现实世界的回顾性研究

Lin Zhou¹, Yaochen Huang^1,2, Yan Qian¹

¹Department of Thoracic Surgery, Tongji Hospital Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.

Discover oncology

|October 28, 2025

概括

与单独的化疗相比,新辅助免疫化疗 (nICT) 在局部晚期食道状细胞癌 (ESCC) 中改善了病理反应和无病生存率 (DFS). 这种方法是安全有效的,支持其融入标准治疗.

科学领域:

在瘤学瘤学.
胃肠病学胃肠病学
临床试验临床试验

背景情况:

食道状细胞癌 (ESCC) 是一个重大的全球健康挑战.
局部发达ESCC的标准治疗包括新辅助疗法,然后进行手术.
优化新辅助剂策略以提高疗效和减少复发至关重要.

研究的目的:

为了比较新辅助免疫化疗 (nICT) 与新辅助化疗 (nCT) 在局部晚期ESCC患者的真实世界的安全性和有效性.
评估与治疗相关的不良事件,反应率和生存结果.

主要方法:

对164名II期-IVA ESCC患者进行了回顾性审查,这些患者接受了nICT或nCT,随后进行了手术.
分析临床特征,与治疗相关的不良事件 (TRAE),放射性和病理反应以及生存结果.
卡普兰-梅尔分析和考克斯回归模型用于评估无病生存率 (DFS) 和总生存率 (OS).

主要成果:

在nICT和nCT组之间,TRAE的发病率相似 (87.3%和86.9%),没有与治疗相关的死亡.
nICT显示病理性完整响应 (pCR: 27.1%与13.0%) 和主要病理性响应 (MPR: 49.2%与30.4%) 的比率显著更高.
nICT表现出优异的DFS (HR=1.696,p=0.016),而整体存活率 (OS) 并没有显著差异 (p=0.064).

结论:

新辅助免疫化学疗法 (nICT) 是对局部发达ESCC的安全有效治疗方法.
与单独的新辅助化疗 (nCT) 相比,nICT改善了病理反应和DFS.
研究结果支持将免疫疗法纳入ESCC的新辅助疗法.

关键词:

没有疾病的生存率.食道状细胞癌是食道的状细胞癌.新辅助化学疗法新辅助化学疗法新辅助免疫化学疗法新辅助免疫化学疗法总体生存率总体生存率

更多相关视频

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

An Ivor Lewis Esophagectomy Designed to Minimize Anastomotic Complications and Optimize Conduit Function

An Ivor Lewis Esophagectomy Designed to Minimize Anastomotic Complications and Optimize Conduit Function

Published on: April 17, 2020

相关概念视频

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.